Retatrutide Phase 3 Data Shows 29% Weight Loss, Rivaling Surgery
Eli Lilly's retatrutide triple agonist achieves 28.7% weight loss in TRIUMPH-4 trial, matching bariatric surgery outcomes and reshaping obesity treatment.
Health press releases
21 press releases about health
Have news about health? Submit a press release free and add “health” as a keyword.